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Leimk€uhler and colleagues demonstrate
that mesenchymal stromal progenitor
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SUMMARY
Functional contributions of individual cellular components of the bone-marrow microenvironment to myelo-
fibrosis (MF) in patientswithmyeloproliferative neoplasms (MPNs) are incompletely understood.We aimed to
generate a comprehensive map of the stroma in MPNs/MFs on a single-cell level in murine models and pa-
tient samples. Our analysis revealed two distinct mesenchymal stromal cell (MSC) subsets as pro-fibrotic
cells. MSCs were functionally reprogrammed in a stage-dependent manner with loss of their progenitor sta-
tus and initiation of differentiation in the pre-fibrotic and acquisition of a pro-fibrotic and inflammatory pheno-
type in the fibrotic stage. The expression of the alarmin complex S100A8/S100A9 in MSC marked disease
progression toward the fibrotic phase in murine models and in patient stroma and plasma. Tasquinimod, a
small-molecule inhibiting S100A8/S100A9 signaling, significantly ameliorated the MPN phenotype and
fibrosis in JAK2V617F-mutated murine models, highlighting that S100A8/S100A9 is an attractive therapeutic
target in MPNs.
INTRODUCTION
Bone-marrow (BM) fibrosis is characterized by continuous
replacement of blood-forming cells in the BM by excessive
scar tissue. Primary myelofibrosis (PMF) is the prototypic
example of progressive development of BM fibrosis. The hall-
mark feature of overt PMF is the excess deposition of extracel-
lular matrix (ECM), which is accompanied by a progressive
loss of hematopoiesis and splenomegaly due to extramedullary
hematopoiesis. Although themolecular alterations in hematopoi-
etic cells, which drive the development ofmyeloproliferative neo-
plasms (MPNs) have been largely defined (Vainchenker et al.,
2011; Rampal et al., 2014), reactive cellular alterations in the
non-hematopoietic compartment remain rather obscure. The
BM morphology in patients with PMF suggests that there is a
stepwise evolution from an initial pre-fibrotic phase to a fibrotic
phase with marked reticulin/collagen fibrosis. However, the
initial changes and sequential events underlying the pre-fibrotic
phase of the disease are not well characterized (Barbui
et al., 2018).
The plethora of stromal cells in a normal hematopoietic stem
cell (HSC) niche (Baryawno et al., 2019; Tikhonova et al., 2019)
Cell Stem Cell 28, 1–16, April 1, 2020 ª 2020 The Author(s). Published by Elsevier Inc. 1
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ll
OPEN ACCESS
Please cite this article in press as: Leimk€uhler et al., Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis,
Cell Stem Cell (2020), https://doi.org/10.1016/j.stem.2020.11.004
Figure 1. Identification of eight distinct non-hematopoietic cell populations
(A) HSPCs transduced with either thrombopoietin (ThPO) cDNA or control cDNA (EV) were transplanted (tx) at 0 weeks; n = 4 mice per time point and condition.
Endpoint: 5 weeks (pre-fibrosis) and 10 weeks (fibrosis). Representative HE and reticulin staining . Scale bar, 50 mm.
(legend continued on next page)
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suggests that different stromal subtypes have distinct roles not
only in normal hematopoiesis but also in BM fibrosis. In solid or-
gan fibrosis, mesenchymal stromal cells (MSCs) are thought to
be a major cellular source for fibrosis-driving cells (El Agha
et al., 2017). These findings are mainly derived from genetic
fate tracing experiments, which allow us to study the cell fate
in response to a pathological stimulus. The well-accepted hy-
pothesis in solid organ fibrosis is that fibrosis-inducing insults,
e.g., pro-inflammatory and pro-fibrotic cytokines, affect MSCs
and lead to a fate switch toward myofibroblasts, which, in turn,
drive fibrosis by depositing ECM. In the BM, we and others
demonstrated that MSCs contribute to fibrosis-driving Gli1+ my-
ofibroblasts (Decker et al., 2017; Schneider et al., 2017), but it re-
mains an open question whether they are the only source of
fibrosis-driving cells in the BM microenvironment or whether
other cell types of the non-hematopoietic BM niche contribute
to the fibrotic transformation. Here, we explored the cellular
composition of the murine and human BM stroma by specifically
profiling purified non-hematopoietic BM cells by scRNA
sequencing (scRNA-seq) to identify fibrosis-driving cells and un-
derlying mechanisms in MPNs using an unbiased approach.
RESULTS
Single-cell RNA-Seq of the BM niche captures eight
major non-hematopoietic cell populations
To dissect the cellular composition and transcriptional changes
of the murine BM stroma in the progression of BM fibrosis, we
profiled non-hematopoietic BM cells by scRNA-seq in ThPO-
induced BM fibrosis (Schneider et al., 2017). We analyzed (1)
initial changes (pre-fibrotic stage) and (2) progression of BM
fibrosis (fibrotic stage). Mice in the ‘‘pre-fibrotic’’ stage showed
features of myeloproliferation and dysmorphic megakaryocytes
but no reticulin fibers (reticulin grade 0, Figure 1A). In the fibrotic
stage, mice developed severe BM fibrosis (Figure 1A). The he-
moglobin (Hb) levels significantly decreased in ThPO-overex-
pressing mice as a surrogate marker for progression of BM
fibrosis (Figure 1B). Mice exhibited significant thrombocytosis,
when transplanted with ThPO-overexpressing HSPCs (Fig-
ure 1B), recapitulating the peripheral myeloproliferative pheno-
type observed in patients. We purified stromal cells from murine
BMs at the pre-fibrotic time point and also the late, fibrotic time
point (Table S1).
Unsupervised clustering of only non-hematopoietic niche cells
identified eight distinct subclusters, which were grouped into
four major cell populations (Figure 1C). The most dominant clus-
ter was characterized by high expression of Leptin receptor
(Lepr), platelet-derived growth factor receptor a (Pdgfra), and
vascular cellular adhesion molecule 1 (Vcam1) as well as high
levels of hematopoiesis supporting factors like Cxcl12, Kit ligand
(Kitl), and angiopoietin (Angpt1), and was thus classified as
MSCs (Figure 1D). The other clusters were identified as osteoli-
neage cells (OLCs; Bglap, Sp7, Alpl), arterial cells/adventitial fi-
broblasts (ACs; Cd34, Ly6a, Ly6c1), and Schwann cell progeni-
tors (SCPs; Mog, Mal, Plp1; Figures 1C and 1D).
Within the Lepr+ fraction, four subpopulations of MSCs were
identified, in line with recent reports (Baryawno et al., 2019; Ti-
khonova et al., 2019). The dominant cluster exhibited an adipo-
genic signature with high levels of Matrix Gla protein (Mgp) and
Adiponectin (Adipoq, Figure S1B) as well as a strong expression
of hematopoiesis supporting genes (e.g.,Cxcl12, Kitl; referred to
as MSC-1; adipogenic MSCs; Figures 1C and 1E). The second
MSC subcluster was characterized by an osteogenic expression
pattern (Spp1, Wif1, Ibsp, Sp7, Bglap; MSC-2; osteogenic
MSCs; Figures 1C and 1E). In the third cluster (MSC-3), high tran-
script levels of genes involved in chromatin remodeling and RNA
processing indicated that these cells are in a transition state be-
tween different functional states of MSCs (Wu et al., 2017; Fig-
ure S1D). Gene set enrichment analysis of cluster 4 (MSC-4) re-
vealed that these cells are strongly primed by a response to type
1 and type 2 interferons (Figure 1E; Figure S1D). Comparison of
the identified MSC marker genes between the different subpop-
ulations and their respective aggregate gene expression analysis
confirmed four distinct MSC populations (Figure 1F; Figure S1E).
We further identified two distinct populations characterized by
a Schwann cell precursor (SCP) signature (Figure 1G) indicated
by Cdh19 expression (SCPs; Figure S1C): non-myelinating
SCPs (nmSCPs) and myelinating SCPs (mSCPs; Figure 1G).
Increased frequency of MSCs and glial cells in BM
fibrosis
All identified cell clusters were present in fibrosis and control, but
significant changes in cellular compositions of particular clusters
were detected (Figure 2A). In fibrosis, MSC-1 and OLCs signifi-
cantly increased in their frequency, while MSC-3 and -4 signifi-
cantly decreased (Figure 2A, right panel). Interestingly, mSCPs
depicted the most drastic cell expansion in fibrosis. SCPs are
cells with high regenerative potential and their contribution to
HSC maintenance was recently demonstrated (Yamazaki et al.,
2011). Potentially, mSCPs expand in response to the myelopro-
liferative stimulus in MPNs as a regenerative mechanism.
Two distinct subpopulations of MSC are functionally
reprogrammed in BM fibrosis to ECM-secreting cells
ECM production is considered the key feature of fibrosis (Fried-
man et al., 2013). We therefore asked which cells show the most
significant expression of ECM specific genes in order to identify
cells that drive BM fibrosis, so called myofibroblasts. We
dissected the expression of gene sets defined for matrisome-
associated genes among the different clusters (Naba et al.,
2016). In particular, MSCs, OLCs, and ACs showed the highest
expression of ECM in fibrosis (Figure 2B) (Naba et al., 2016).
(B) Hemoglobin (Hb) and platelet counts over time (mean ± SEM). Two-way-ANOVA with post hoc pairwise t test was used.
(C) UMAP of the non-hematopoietic BM niche identified by unsupervised clustering (n = 2,294 cells).
(D) Average gene expression of top marker genes within major cell populations (left panel). Feature plot of top markers in UMAP (right panel) is shown. Wilcoxon
rank-sum test, p < 0.01). A full list of marker genes and corresponding GO terms is in Table S2.
(E) Heatmap of different MSC marker genes. Wilcoxon rank-sum test, p < 0.01.
(F) Venn diagram of the four identified MSC populations. Shared markers are highlighted in intersections.
(G) Heatmap SCP marker genes. Wilcoxon rank-sum test, p < 0.01.
See also Figure S1 and Tables S1 and S2.
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Figure 2. Mesenchymal stromal cells –1 and –2 represent the fibrosis-driving cells in ThPO-induced bone-marrow fibrosis
(A) Left panel: UMAP of non-hematopoietic cells frommice transplanted with thrombopoietin (ThPO; blue) or empty vector (EV; red; 5 and 10 weeks). Right panel:
bar plot of cells per cluster (ThPO versus EV). Normalization to overall number of input per condition is shown. Fisher’s exact test with Bonferroni correction
was used.
(B) Ridgeline plot comparing expression of NABA matrisome-associated gene sets (ThPO; blue versus control EV; red) condition. Competitive gene set
enrichment analysis was used.
(C) Normalized differential gene expression (ThPO versus EV) of indicated genes in MSCs (Wilcoxon rank-sum test, two tailed).
(D) Overlap of the non-hematopoietic compartment and FACS Gli1+ cells in UMAP space.
See also Figure S2 and Tables S3 and S4.
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Figure 3. Mesenchymal stromal cells –1 and –2 are reprogrammed in pre-fibrosis and acquire a pro-fibrotic phenotype in fibrosis
(A) UMAP of non-hematopoietic single cells in pre-fibrosis (5 weeks; red) and fibrosis (10 weeks; blue).
(B) Bar plot of cells per cluster in ThPO versus EV after normalization to input per condition. Fisher’s exact test with Bonferroni correction was used.
(legend continued on next page)
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Importantly, only MSC-1 and MSC-2 showed a significant upre-
gulation of ECM proteins in BM fibrosis, indicating that these two
populations are the cellular drivers of the fibrotic progression and
acquire myofibroblast characteristics. The most significantly de-
regulated genes in MSCs were grouped into (1) downregulated
genes and (2) upregulated genes with onset of the MPN pheno-
type (Figures 2C; Figure S2A). The downregulated genes
comprised (1) MSCmarkers (Vcam, Lepr, Adipoq) and (2) hema-
topoiesis support (Kitl, Il7, Igf1, Cxcl12, Csf1, Bmp4). The upre-
gulated genes were defined through four major biological pro-
cesses: (1) secreted factors (S100a8, S100a9, Pdgfa), (2)
osteogenesis (Mgp, Fndc1), (3) neoangiogenesis (Vegfa, C3),
and (4) ECM synthesis (Col8a1, Col1a1).
As MSC-1 and -2 by gene expression seemed to be the most
primitive MSCs and fibrosis-driving cells, we wondered whether
they can be discriminated by surface markers from MSC-3 and
-4. We isolated MSC-1 and -2 (Pdgfra/b+, Vcam1+, CD63+,
Lamp1+) and MSC-3 and -4 (Pdgfra/b+, Vcam1+, CD63–, and
Lamp1–) by fluorescence-activated cell sorting (FACS) for sub-
sequent functional testing (Figures S2B and S2C). MSC-1 and
-2 formed significantly more colony-forming units fibroblast
(CFU-F) and had a higher cell-division rate, as compared to
MSC-3 and MSC-4, highlighting their progenitor status (Figures
S2D and S2E). Importantly, they were also more sensitive to pro-
fibrotic transforming growth factor (TGF)-b stimulation in vitro as
indicated by higher upregulation of Col1a1 and Acta2 mRNA as
compared to MSC-3 and -4 (Figure S2F). In the context of differ-
entiation into fibrosis-driving ɑ-SMA and Col1a1 expressing
cells, MSC-1 and -2 strikingly downregulatedCxcl12, supporting
our finding that these cells lose their hematopoiesis support dur-
ing myofibroblast differentiation. Quantification of the frequency
of MSC-1 and -2 in ThPO-induced BM fibrosis further supported
the finding that these progenitor subsets are expanded in fibrosis
while MSC-3 and -4 were decreased in their frequency (Fig-
ure S2G), in line with the data on the single-cell level (cf.
Figure 2A).
Gli1+ cells comprise fibrosis-driving MSC-1 and -2 and
Schwann cell precursors
Surprisingly, SCPs and mSCPs, which most drastically
expanded in fibrosis, only revealed minor transcriptomic
changes in ThPO versus EV conditions. However, mSCPs were
characterized by high and specific expression of Interleukin-33
(Il-33) and Prostaglandin D2 synthase (Ptgds), implied to play
central roles in solid organ fibrosis (Ito et al., 2012; Kotsiou
et al., 2018) (Figure S2H). Previously, we demonstrated that
Gli1+ cells are fibrosis-driving cells in the BM. To reliably label
Gli1+ cellular subsets of the BM niche, we used Gli1CreER;tdTo-
mato reporter mice (Schneider et al., 2017) for FACS-based pu-
rification for scRNA-seq. We integrated the data with stromal
cells derived from the negative selection approach (Figure 2D;
cf. Figure 1C; Table S1). Interestingly, Gli1+ cells are mostly
MSCs, comparable to LepR+ cells but particularly annotated
as MSC-1 (41%) and -2 (19%), the fibrosis-driving cells, explain-
ing our previous finding that genetic ablation of these cells ame-
liorates BM fibrosis (Schneider et al., 2017). Gli1+ cells are also
represented in the mSCP cluster (26%), in line with MSC being
derived from neural crest and comparable to the Nestin+ popu-
lation, which also contains SCPs (Isern et al., 2014).
MSCs are functionally reprogrammed in pre-fibrosis and
acquire a secretory, fibrotic, and osteogenic phenotype
in manifest fibrosis
Next, we asked which cellular composition and transcriptional
changes are characteristic for niche cells in the stepwise evolu-
tion of BM fibrosis (Figures 3A and 3B). Fibrosis-inducing MSC-
1, both SCP populations and OLCs expanded in the pre-fibrotic
phase while all other MSC populations decreased. In manifest
fibrosis, IL33-expressing mSCPs, OLCs, and ACs expanded
(cf. Figure 1A). To understand overall transcriptional changes
across the different populations in pre-fibrosis and fibrosis, we
performed differential expression analysis. All MSC clusters
(MSC-1 to -4) showed mostly downregulated genes in pre-
fibrosis compared to control (Figure 3C; Figure S3A) while
none of the other niche cell types showed transcriptional
changes, neither in pre-fibrosis nor in fibrosis (Figures S3B
and S3C).
In pre-fibrosis, fibrosis-driving MSC-1 revealed ER stress and
a significant downregulation of genes compared to the control
condition (Figure 3C). The downregulated genes in MSC-1 and
-2 indicated significant ‘‘transcriptional reprogramming’’ of these
populations with loss of their core cellular characteristics: (1) loss
of niche and hematopoiesis support as well as neurotrophic
(e.g., Fzd1, Cebpb) and vascular signaling (e.g., Foxc2, Hes1),
(2) loss of MSC multipotent progenitor status (e.g., Arntl, Arhg-
dib, Ddr1, Lamb1), (3) decreased cellular function (e.g., Mapk3,
Msn), and (4) metabolic inactivation (e.g., Cat, Tblxr1, Dgat1,
Pank2). In manifest fibrosis, MSC-1 and -2 upregulated
numerous genes, which confirmed the functional reprogram-
ming with loss of niche-supportive characteristics and loss of
multipotent progenitor status (Figure 3D). MSC-1 was character-
ized by marker genes for myofibroblasts (e.g., upregulation of
Igfbp7, Limch-1, Wisp-2) and extensive ECM and collagen syn-
thesis (mainlyCol1a1,Col8a1). Changes in MSC-2 indicated that
these cells differentiate into (1) myofibroblasts (e.g., upregulation
of Limch1, Gas7, Acta1), (2) osteoblasts (e.g., upregulation of
Bglap), and (3) also glial cells (e.g., upregulation of S100a8,
S100a9), potentially also compensating for the neuropathy and
Schwann cell death in MPNs.
To validate our hypothesis that MSCs are reprogrammed in
early stages of fibrosis and are fibrosis-driving myofibroblasts,
which do not support normal hematopoiesis in manifest fibrosis,
we defined gene sets based on the literature (Table S4) to inter-
rogate ‘‘hematopoiesis support,’’ ‘‘MSC progenitor phenotype,’’
‘‘non-collagenous ECM,’’ and ‘‘collagenous ECM’’ and plotted
the dynamics of these gene sets in pre-fibrosis and fibrosis
(C and D) Volcano plot (ThPO versus EV) of differentially expressed genes (Wilcoxon rank-sum test, two tailed; calculated per cluster individually; top panel).
Associated gene ontology terms (biological processes; BP; Fisher exact test; single tailed) plotted semantically (bottom panel) in (C) pre-fibrosis and (D) fibrosis.
(For a complete list of GO-terms and corresponding genes, see Tables S2 and S3.)
(E) Ridgeline plot of functional gene sets (as indicated) in ThPO (blue) versus EV (red). Competitive gene set enrichment analysis.
(F) PROGENy analysis of MSC-1 andMSC-2 in pre-fibrosis and fibrosis. Sampling based permutation (10,000 permutations). Pathway activity scores as Z scores.
See also Figure S3 and Tables S3 and S4.
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Figure 4. Mesenchymal stromal cells –1 and –2 are reprogrammed in JAK2V617F-induced primary myelofibrosis
(A) Representative HE and reticulin staining of JAK2V617F-induced fibrosis or control (EV, n = 4 mice per condition). Scale bar, 50 mm.
(B) Hemoglobin levels (mean ± SEM). Two-way ANOVA with post hoc pairwise t test was used.
(C) UMAP of non-hematopoietic BM cells (n = 1,292 cells).
(D) Top marker genes. Wilcoxon rank-sum test, p < 0.01. A full list of marker genes and corresponding GO terms is provided in Table S2.
(E) Bar plot of cells number in JAK2V617F versus control (EV) after normalization to total number. Fisher’s exact test with Bonferroni correction was used.
(legend continued on next page)
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(Figure 3E). In pre-fibrosis, MSCs are characterized by downre-
gulated hematopoiesis support (MSC-3 and -4) and MSC char-
acteristics (MSC-1, -2, -3). Even at this early time point, genes
defining non-collagenous ECM proteins were significantly upre-
gulated mainly in MSC-1 and -2, the fibrosis-driving cells. In
overt fibrosis, MSCs showed highly significant downregulation
of hematopoiesis support, MSC characteristics, and strong up-
regulation of ECM proteins (in all MSC clusters) and collagen
(in MSC-1 and -2).
By comparing the differential expression signature of our sin-
gle cell data with 14 signatures of pathway perturbation in pre-
fibrosis and fibrosis (pathway responsive genes [PROGENy]
analysis; Schubert et al., 2018), we detected increased activity
of pro-inflammatory and pro-angiogenic pathways, specifically
tumor necrosis factor (TNF)-a, and also of the JAK-STAT
pathway, in fibrosis-driving MSC-1 and -2 (Figure 3F). Interest-
ingly in pre-fibrosis, pro-fibrotic TGF-b signaling was signifi-
cantly decreased in MSC-1 and -2, while in fibrosis it showed
the most extreme upregulation (Figure 3F). The TGF-b pathway,
considered to be the master regulator of fibrosis (Meng, Nikolic-
Paterson and Lan, 2016), thus seems to play a central role in BM
fibrosis but is not one of the earliest events, which are rather
inflammation driven.
Single-cell analysis of niche cells confirmsMSC-1 and -2
as fibrosis-driving cells and expansion of mSCPs in
JAK2(V617F)-induced myelofibrosis
We validated our findings by using retroviral expression of the
JAK2V617F mutation, which is the most common mutation in pa-
tients (Mullally et al., 2012; Schneider et al., 2017). After
24weeks, mice developed severe fibrosis (Figure 4A), low hemo-
globin levels, and high platelets (Figure 4B; Figure S4A).
Single cell RNA-seq recovered 1,292 cells non-hematopoietic
cells, with an average of 1,000 genes per cell (Table S1). Exactly
the same eight populations identified in the ThPO-induced BM
fibrosis model were detected (Figure 4C; Figure 4D cf. Figure 1D;
Figures S3B–S3D): (1–4) MSCs (MSC-1: adipogenic, MSC-2:
osteogenic, MSC-3: transition, MSC-4: interferon high, (5 and
6) Schwann cell precursors (SCPs; 1: non-myelinating SCPs,
nmSCPs; 2: myelinating SCPs, mSCPs), (7) osteoblastic lineage
cells (OLCs), and (8) arterial fibroblasts (ACs). Cells from all iden-
tified populations were present in both the JAK2V617F-induced
fibrosis and in non-fibrotic control mice. The integration of all
cells indicated an expansion of MSC-1, MSC-4 (interferon-
primed), and mSCPs in fibrosis compared to control (Figure 4E).
The expansion of mSCPs was comparable to ThPO-induced BM
fibrosis, again highlighting the role of glial cells in MPNs.
JAK2V617F induces a phenotypic switch toward
myofibroblasts and osteoblasts in MSC-1 and -2
MSC-1 and -2 andOLCs expressed the highest number of differ-
entially expressed genes compared to the control condition (Fig-
ure 4F). MSC-1 and -2 were characterized by a strong osteo-
genic signature (ossification) in line with the advanced fibrosis
grade (MF3). In MSC-1 and -2 the strong upregulation of Bglap
(bone gamma carboxyglutamate protein, also known as Osteo-
calcin) indicated an osteogenic differentiation bias. In MSC-2,
Spp1 (Secreted Phosphoprotein 1; also known as Osteopontin)
was significantly upregulated. MSC-2 showed a strong inflam-
mation/wound healing signature. MSC-1 and -2 further acquired
a ‘‘myofibroblast’’ phenotype (upregulation of Limch1; Dcn) and
expression of Col1a1, Col8a1, Fndc1 (Table S3).
Our data show that MSC-1 and -2 in JAK2V617F-induced BM
fibrosis acquire an osteogenic and myofibroblast phenotype
with loss of MSC progenitor characteristics. SCPs and
ACs only showed few changes in their transcriptome in
JAK2V617F-induced PMF (Figure S4E). Exactly as observed in
the ThPO-model of BM fibrosis, the expanded mSCP population
was characterized by expression of the fibrosis-relevant genes
Il33 and Ptgds (Figure S4F).
MSC-1 and MSC-2 showed the highest upregulation of ECM
proteins, in particular, ‘‘core matrisome,’’ collagen, and glyco-
proteins in myelofibrosis, confirming that these two MSC popu-
lations are the cellular drivers of fibrosis and acquire myofibro-
blast characteristics (Figure 4G). The significantly upregulated
pathways in MSC-1 and -2 were TGF-b, TNF-a, and also JAK-
STAT signaling, exactly as seen in the ThPO model, highlighting
the importance of these pathways in BM fibrosis (Figure 4H).
Transcriptionally inferred cellular interactions decrease
in pre-fibrosis while niche cells show a self-supporting
network in fibrosis
We aimed to dissect how cellular interactions within the niche
affect the perturbation of signaling pathways detected in fibrosis
by employing CellphoneDB (Efremova et al., 2020; T€urei et al.,
2016). Most ligand-receptor interactions were markedly
decreased in ThPO-induced pre-fibrosis (Figure 5A; Table S5).
In fibrosis (ThPO-induced), an overall decrease of cellular inter-
actions was detected, while interactions between OLCs and
SCPs increased. Interactions involving fibrosis-driving MSC-1
andMSC-2 showed distinct upregulation, indicating their activa-
tion as fibrosis-driving cells (Figure 5A). In the JAK2V617F dataset,
a strong upregulation of intercellular communication between all
niche populations was observed (Figure 5A). These findings sup-
port the hypothesis of a progressive reprogramming of the niche
in fibrosis: niche populations first lose their physiological interac-
tions and are then remodeled into a self-supporting network in
advancing fibrosis.
We quantified the absolute number of interactions for each
unique ligand and ranked them by their absolute frequency (Fig-
ure 5B). ECM proteins (Col1a1, Fn1) and integrins involved in
cell-ECM-interactions (Itgb1, Itga1, Itgav) were among the top
hits. Tgfb1, Egfr, and Nfkb1 were also among the top 10 most
abundant ligands. We next focused on interactions involving
fibrosis-driving MSC-1 and -2 and Tgfb1 as a master switch in
fibrosis (Figure 5C, first and second panel). Interestingly, MSCs
themselves were predicted to be a main source of Tgfb1-driven
(F) Volcano plot; Wilcoxon rank-sum test, two tailed; calculated per cluster between JAK2V617F and JAK2WT (top panel). Associated gene ontology terms
(biological processes; BP) plotted semantically (bottom panel) are shown. (For a complete list of GO-terms and corresponding genes, see Table S3.)
(G) Ridgeline plot for matrisome gene sets in MSC and OLC clusters (JAK2V617F; blue versus control; red) condition. Competitive gene set enrichment analysis
was used.
(H) PROGENy analysis of MSC-1 and MSC-2. Sampling based permutation (10,000 permutations). Pathway activity scores as Z scores are shown.
See also Figure S4 and Tables S1, S2, S3, and S4.
ll
OPEN ACCESS Article
8 Cell Stem Cell 28, 1–16, April 1, 2020
Please cite this article in press as: Leimk€uhler et al., Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis,
Cell Stem Cell (2020), https://doi.org/10.1016/j.stem.2020.11.004
Figure 5. Tgfb1-driven cellular interaction and biased differentiation of MSCs in MPN
(A) Network plot of ligand-receptor activity in control and fibrosis.
(B) Bar plot of top 10most abundant ligands in all inferred ligand-receptor interactions per dataset. Datasets are shown side by side (ThPO: pre-fibrosis, light blue;
ThPO: fibrosis, dark blue; JAK2V617F: fibrosis, green).
(legend continued on next page)
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cellular communication and showed upregulation of auto- and
paracrine Tgfb1 signaling in manifest fibrosis. Tgfb1-mediated
signals between OLCs and MSC-1/2 decreased over time,
whereas those originating from SCPs increased. This is particu-
larly interesting as Schwann cells have been described to partic-
ipate in BM TGFb G signaling (Yamazaki et al., 2011). In
JAK2V617F-induced myelofibrosis an upregulation of Tgfb1
signaling in the niche was also observed. Our findings suggest
that niche intrinsic TGFb signaling contributes to the overall re-
programming of MSC-1 and MSC-2 in fibrosis.
MSCs have higher differentiation propensity toward
SCPs and osteoblasts in PMF
To understand the differentiation capacities of MSCs in fibrosis,
we performed cell-fate trajectory analysis and identified a tran-
scriptional continuum of the 4 MSC populations. SCPs and
OLCs represented two distinct differentiated cell populations
(terminal branch) starting at MSCs (Figure 5D). The trajectory
implied a transition from MSC-1 and MSC-2 through MSC-3,
as a transitory state, to one of the two terminal branches (Fig-
ure S5A).MSC-2, as osteogenic primedMSCs, showed the high-
est tendency toward osteoblastic differentiation (Figure 5D) and
OLCs increased in fibrosis (Figure 5E). Interestingly, in the
ontogeny of the BM HSC niche, some MSCs expressing Nestin
share a common origin with sympathetic peripheral neurons
and also glial cells. This might explain why some MSCs retain
the plasticity to differentiate into glial cells/SCPs and Gli1+ cells
can also be found in the SCP cluster ((Cai et al., 2017); cf. Fig-
ure 2D). To validate differentiation of MSCs into SCPs, we
applied published differentiation protocols. MSCs in the differen-
tiation condition showed a significant upregulation of S100b and
p75 neurotrophin receptor (p75ntr), indicating differentiation into
SCPs (Figure S5B). We thus hypothesize that mutant (and
fibrosis-inducing) HSCs can induce the terminal differentiation
of MSCs into (1) matrix-secreting myofibroblasts, (2) osteoline-
age cells, or (3) to a lower extent Schwann cell precursors/
Schwann cells.
Branched expression analysis modeling (BEAM) (Qiu et al.,
2017) revealed a gradual loss of MSC-specific markers along
the trajectory, which was particularly pronounced in the transdif-
ferentiation toward SCPs (LepR). At the same time these cells
acquire expression of S100b, a well-known marker for the
Schwann cell lineage, at progenitor stages, which is also ex-
pressed on MSCs differentiated into SCPs (Figure 5F). The
expression of S100b at a later stage is associated with
increasing expression of Ncam1 (CD56) in both OLCs and
SCPs (Figures 5F and 5G). Projecting the measured expression
levels to the pseudotime trajectory confirmed a rather sparse
pattern of cells differentiating toward SCPs, in particular,
compared to OLCs (Figures 5F and 5G).
We next wondered whether the strong bias toward OLCs and
myelinating SCP differentiation is reflected in patient samples.
Systematic analyses of BM biopsies showed that spindle-
shaped CD56/NCAM positive cells are activated from the
endosteal niche (normal location) in the progression of BM
fibrosis when they can be found abundantly in the marrow (Fig-
ures S5C–S5E, Figures S5D and S5E). S100b positive cells in
control BMs (MF0) were mostly located in a periarteriolar local-
ization (Figure S5F). In advanced MF, they were mobilized from
their normal niche and were increased in their frequency (Fig-
ures S5F and S5G). Double immunohistochemistry for IL-33
and S100b confirmed occasional double positive spindle-
shaped cells in the BM, as observed in our scRNA-seq data
(Figure S5H).
Single-cell RNA-seq of the BMniche in PMF patients and
controls confirms the molecular reprogramming of
fibrosis-driving MSCs
Next, we validated our findings in clinical patient samples. One of
the major challenges in late-stage myelofibrosis is that accessi-
bility of liquid BM by aspiration is often limited (dry tap), and he-
matopoietic tissue for diagnosis is only available in the form of a
BM biopsy. We received ~5 mm long pieces of biopsies (excess
material not needed for diagnostics; Figure S6A) of two control
patients (Figure 6A; Figure S6B) and 1 patient with JAK2V617F
MPNs/PMF (VAF 13% in BM; MF grade 2–3; Figure 6A; Fig-
ure S6C). Stromal cells were enriched from BM biopsies after
crushing and flow-based cell sorting of CD45–/CD71–/
CD235a–/7AAD– cells (Figure S6D; Figure 6B; Table S1).
Unsupervised clustering identified 5 distinct major cell popula-
tions (Figure 6B): two hematopoietic and three stromal cell
clusters. Stromal cell clusters were defined as (1)MSCs, (2) fibro-
blasts (Fib), and (3) Schwann cells (SC). MSCs were character-
ized, in line with the murine data, by high expression of Leptin
receptor (LEPR), platelet-derived growth factor receptor b
(PDGFRB), and CXCL12 (Figure 6C). Fibroblasts do not express
these MSC-specific markers but express ECM proteins as
collagen 1a1 (COL1A1) and fibronectin-1 (FN1); (Figure 6C).
The Schwann cell cluster showed concordance with the murine
dataset, in particular, in expression of myelin-associated oligo-
dendrocyte basic protein (MOBP). The hematopoietic clusters
were characterized by megakaryocyte-specific (Meg) markers
(PF4, PPBP, and ITGA2B) and markers for myeloid cells
(S100A8, ELANE,MPO); Figure 6C). Importantly, all cell clusters
were present in the control and PMF sample in comparable dis-
tribution (Figure 6B).
Strikingly, MSCs transcriptionally showed loss of their core
cellular characteristics as (1) downregulated niche and hemato-
poiesis support and (2) decreased MSC multipotent progen-
itor status (MSC signature; Figure 6D). They further showed
(C) Top 20 deregulated interactions mediated by Tgfb1 targeting MSC-1 and MSC-2. Interactions ordered based on difference in mean LR expression between
fibrosis and control. (For a full list of inferred ligand-receptor interactions, see Table S5.)
(D) Reconstructed cell differentiation trajectory of MSC populations.
(E) Bar plot of numerical changes between fibrosis and control in respective branches as identified in pseudotime analysis. Fisher’s exact test with Bonferroni
correction was used.
(F) Expression levels of highlighted genes projected onto differentiation trajectory in pseudotime space.
(G) Expression levels of indicated genes with respect to their pseudotime coordinates. Black line indicates differentiation trajectory toward OLC branch and
dotted lines toward SCP branch.
See also Figure S5 and Table S5.
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Figure 6. MSCs are fibrosis-driving cells in patients characterized by upregulation of S100A8/A9
(A) Diagnostic BM images of the patients. Representative H&E and reticulin stainings. For additional images (all controls) and detailed patient characteristics, see
Figure S5.
(B) UMAP of cells in 1 PMF patient (MF2, n = 243 cells) and two control patients (MF0, n = 255 cells). In the left panel, cells are color coded by their annotated
cellular identity, and in the right panel, by their patient source.
(C) Top marker genes. Wilcoxon rank-sum test, p < 0.01.
(D) Ridgeline plot comparing PMF (blue) versus control (red) condition. Competitive gene set enrichment analysis was used.
(E) PROGENy analysis. Sampling-based permutation (10,000 permutations). Pathway activity scores are given as Z scores.
(legend continued on next page)
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significant upregulation of ECM proteins, specifically collagens,
in PMF compared to normal BMs. Exactly as observed in themu-
rine models, significantly upregulated pathways in those cells
were JAK-STAT and TGF-b in MSCs as fibrosis-driving cells
(Figure 6E).
The alarmin heterocomplex S100A8/S100A9, which can be
considered a myeloid marker and is highly expressed in myeloid
cells, was significantly upregulated in non-hematopoietic stro-
mal cells that do not show S100A8/S100A9 expression in steady
state (Figure 6F), in line with our murine datasets (Figure S6E).
Previous data indicate that upregulated S100A8/S100A9
expression (and release) can be a stress response, impair normal
hematopoiesis, and induce genotoxic stress and might thus
reflect disease progression (Schneider et al., 2016; Vainchenker
and Plo, 2016; Yang et al., 2016; Zambetti et al., 2016; Ribezzo
et al., 2019). There is indication that S100A8/S100A9 exerts its
biological effects specifically in the vicinity of the producing
cell (Vogl et al., 2018). In PMF, this means that MSCs upregulate
the alarmin complex and mainly affect HSCs in their vicinity but
also megakaryocytes and Schwann cells, which in turn start to
express S100A8/S100A9.
The S100A8/S100A9-driven cross-talk in PMF patients origi-
nated strongly from myeloid cells. Importantly, the interaction
with almost all niche cells and specifically MSCs was increased
in PMF (Figure S6F). This provides further evidence for the broad
effect of S100A8/A9 on populations involved in fibrotic transfor-
mation. In PMF, megakaryocytes dominated cellular interactions
with all niche cells while other hematopoietic-niche cell interac-
tions rather decreased (Figure 6G). As seen in the murine
models, megakaryocyte-derived TGFB1 signals were highly up-
regulated (Figure 6H) while TGFB1 signals from other clusters,
such as fibroblasts and myeloid cells, were downregulated in
PMF (Figure 6I). Other megakaryocyte-derived mediators with
implication in PMF were also upregulated: PF4 (CXCL4), its ho-
molog PF4V1 and platelet-basic protein precursor (PPBP)
(Schneider et al., 2017; Gleitz et al., 2020). Signaling through
pro-fibrotic receptors as VCAN and GF2 was also upregulated
in PMF compared to controls (Figure 6J). This provides evidence
that the interaction between megakaryocytes and fibrosis-
driving MSCs is central in the priming and fibrotic transformation
of MSCs.
The alarmin S100A8/S100A9 complex is systemically
increased in MPNs and stromal alarmin expression
marks the onset and progression of BM fibrosis
Our data in patient samples and murine models indicated that
S100A8/S100A9 expression in MSCs is already upregulated in
pre-fibrosis and significantly increased in fibrotic stages in
almost all niche cells, suggesting S100A8/S100A9 as a sensitive
marker for disease/fibrosis progression. We thus asked whether
S100A8, one subunit of the heterodimeric complex, is also
secreted and can mark the progression of BM fibrosis in pa-
tients. We quantified S100A8 in plasma samples (peripheral
blood) from MPN patients by ELISA (Figure S7A). S100A8 was
significantly increased in MPN patients (Figure 7A) and demar-
cated the transition fromMF0 toMF1 and higherMF grades, indi-
cating S100A8 as a sensitive marker for fibrosis onset or pro-
gression in PMF when follow-up samples are taken (Figure 7B).
The S100A8 plasma concentration did not correlate with white
blood cell counts, emphasizing that the elevated concentration
is not only caused by the disease-specific myeloproliferation
(Figure S7B). In previous work, we linked increased S100A8
expression in the stroma (in MDS) to decreased hematopoiesis
support (Ribezzo et al., 2019). We performed immunohisto-
chemistry for S100A8 on BM biopsies (Figures S7C and S7D).
S100A8+ hematopoietic cells were expanded in MPNs in MF
grade 0–1 but rather decreased in MF grade 2–3 due to pro-
gressing fibrosis (Figure 7C). Detailed analysis of S100A8
expression in the BM revealed distinct staining and distribution
patterns, which we defined as four grades of S100A8 expression
(Figures 7D and 7E): in grade 0 the S100A8 expression is limited
to hematopoietic/myeloid cells, in grade 1 interstitial S100A8
staining is detected, in grade 2 distinct patches of stromal cells
stain positive for S100A8, in grade 3 the S100A8 expression is
significantly reduced in hematopoietic cells, but dense patches
of positively stained stromal cells can be found (Figure S7D).
Control BMs were consistently graded as grade 0 while, in
particular, S100A8 grade 2 marked the progression of BM
fibrosis, suggesting that stromal expression of the heterodimeric
S100A8/S100A9 alarmin complex is a sensitive marker for dis-
ease progression (Figure S7E).
S100A8/S100A9 is a therapeutic target in PMF
To determine whether the alarmin complex is a therapeutic
target in MPNs associated with fibrosis, we tested Tasquinimod
in the murine JAK2V617F MF model (Figure S7F). Tasquinimod
binds to the S100A8/S100A9 alarmin heterodimer and impedes
its interaction with TLR4 and RAGE receptors (Isaacs et al.,
2006). Tasquinimod treatment ameliorated the myeloprolifera-
tion in JAK2V617F mice comparable to leukocyte, hemoglobin,
and platelet counts in controls (Figure 7F; Figures S7G and
S7H). Severe splenomegaly, which is a major clinical manifesta-
tion in PMF patients, was observed in vehicle-treated JAK2V617F
mice but completely normalized with Tasquinimod treatment
(Figures 7G and 7H). Importantly, Tasquinimod treatment in
JAK2V617F mice significantly reduced the fibrosis grade and
restored the BM architecture in MPNs (Figure 7I; Figures
S7I–S7J).
To investigate the direct effect of Tasquinimod on the fibrotic
transformation of MSCs, we induced the fibrotic transformation
(F) Ridgeline plot of S100A8/A9 expression in PMF (blue) or control (red). Significance estimated by modeling the dropout rate as a binomial process with the
observed dropout rate per condition as estimator of p for both conditions, respectively.
(G) Network plot of ligand-receptor activity in PMF compared to control.
(H) Bar plot of top 10 most abundant ligands in all inferred ligand-receptor interactions.
(I) Sankey plot of top 20 deregulated TGFB1-mediated ligand-receptor interactions. The absolute difference in mean LR expression was used as a metric for the
extent of deregulation.
(J) Sankey plot of top 20 deregulated ligand-receptor interactions mediated by PF4, PF4V1, or PPBP. The absolute difference inmean LR expression was used as
a metric for the extent of deregulation.
See also Figure S6 and Tables S1, S2, S3, S4, and S5.
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of isolated primary MSCs by addition of TGF-b as a strong pro-
fibrotic stimulus in the absence or presence of Tasquinimod. The
addition of TGF-b induced the differentiation of MSCs into
a-SMA-positive myofibroblasts. Tasquinimod significantly
reduced the frequency of a-SMA positive myofibroblasts but
did not completely block this important step in the fibrotic
transformation.
These results provide strong indication that S100A8/S100A9
plays a central role in the fibrotic transformation, directly on
MSCs but also through the hematopoietic-stromal cross-talk,
and that its pharmacological targeting ameliorates both the
MPN phenotype but also fibrosis and exerts effects on stromal
cells and the mutant hematopoietic clone.
DISCUSSION
Our findings supplement the picture of the BM microenviron-
ment in the presence of a malignant hematopoietic MPN clone,
which induces a regenerative but pro-fibrotic environment lead-
ing to (mal-)differentiation of distinct MSC populations with loss
of their normal function. MSCs are increasingly recognized as a
major source of fibrosis-associated myofibroblasts in various or-
gans (El Agha et al., 2017). These findings are almost solely
based on genetic fate tracing, which is the gold-standard
approach for studying cell-fate switching in response to patho-
logical stimuli (Kramann et al., 2015; Schneider et al., 2017).
Here, we applied single-cell RNA-seq to better understand fate
switching of distinct precursor cells/MSC populations during
injury induced by a malignant clone. Several key observations
were only possible due to the single cell-level resolution of our
study, highlighting the power of single-cell technologies in un-
derstanding disease pathology and biomarker identification for
pre-fibrotic stages.
We demonstrate that two distinct MSC populations (MSC-1
andMSC-2) are themain drivers of BM fibrosis in twowell-estab-
lished models. These two MSC populations are LepR+, adipo-
genic-, or osteogenic-biased progenitor populations under
steady-state conditions with high expression of Cxcl12, indi-
cating their hematopoiesis-supporting capacity. Importantly,
the different MSC populations identified in our study are in line
with the four different MSC populations described before using
either lineage-negative selection as in our approach; (Baryawno
et al., 2019) or sort purification of LepR-positive cells (Tikhonova
et al., 2019), respectively. Gli1+ cells on the single-cell level are
Figure 7. Spatial kinetics of S100A8/S100A9 detects disease progression in MPN and their pharmacological targeting ameliorates the
disease
(A) ELISA of S100A8 (and S100A9) in MPN (blue) and controls (red) plasma. Two-tailed, two-sample Welch test was used.
(B) ELISA of S100A8 (and S100A9) in MPN with different MF grades (blue) and controls (red) plasma. Mean ± SEM. One-way-ANOVA with post hoc Tukey’s
was used.
(C) Frequency of S100A8+ cells BM biopsies; n = 64 patients. One-way-ANOVA with post hoc Tukey’s HSD was used.
(D and E) Grading of S100A8 in the non-hematopoietic compartment in BM biopsies. Scale bar, 100 mm. n = 64 patients. Kruskal-Wallis H test with post hoc
Wilcoxon rank-sum test was used. p values were adjusted for multiple hypothesis testing by the Holm-Bonferroni method.
(F) White blood cell counts of WT mice transplanted with either JAK2V617F (blue) or JAK2WT overexpressing HSPCs (red) each either treated with Tasquinimod
30 mg/kg/day or vehicle control. Two-way repeated ANOVA pairwise comparisons were analyzed by estimated marginal means.
(G) Spleens at sacrifice as indicated.
(H) Relative spleen weights. Mean ± SEM. One-way-ANOVA with post hoc Tukey’s HSD.
(I) Reticulin (MF) grade. Kruskal-Wallis H test with post hoc Wilcoxon rank-sum test.
See also Figure S6.
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MSCs, which are enriched for MSC-1 and -2, as fibrosis-driving
cells and also in part have SCP character. These data highlight
that some MSCs are also derived from neural crest and thus
have a common origin with sympathetic peripheral neurons and
glial cells, reflected by their expression profile (Isern et al.,
2014). Given their expression profile and the pseudotime anal-
ysis, MSC-1 and -2 seem to be (multipotent) mesenchymal pro-
genitor cells, which means mesenchymal cells that are capable
of differentiating into a limited number of cell types. These two
progenitor populations are the predominant Col1a1-producing
cells in overt BM fibrosis. Importantly, collagen I is considered
the hallmark ECM protein of fibrosis. Our data identified these
two populations as key drivers of myelofibrosis and add novel
insight into the role of these populations in this most extensive
form of remodeling of the BM microenvironment. The functional
characterization of sort-purified MSC- 1 and -2 confirmed the
transcriptional data on the single-cell level and demonstrated
their progenitor profile. Thus, the proposed antibody panel for
enrichment of MSC-1 and -2 is also interesting for approaches
requiring an enrichment of more immature progenitor cells,
e.g., in regenerativemedicine. It is important to note that in all ap-
proaches we were able to cover the majority of cell populations
known to be part of the hematopoietic niche, yet only MSCs
proved to be responsive to the malignant hematopoietic clone
with regards to ECM production. This makes therapeutical tar-
geting of the niche highly attractive (Curto-Garcia, Harrison,
and McLornan 2020; Méndez-Ferrer et al., 2020; Schneider
et al., 2017).
We demonstrate that MSCs are functionally reprogrammed in
fibrosis with loss of their progenitor status and normal function in
the BM microenvironment. We show that the reprogramming of
MSCs is a stepwise process, which starts with loss of ‘‘MSC
characteristics’’ in all 4 MSC populations, not only in the
fibrosis-driving ones, already in the pre-fibrotic phase. This indi-
cates that all MSC populations react to the fibrosis-inducing he-
matopoietic clone while only MSC-1 and -2 are capable of differ-
entiation into ECM-producing myofibroblasts. Interestingly, all
MSC subsets lose their hematopoiesis support over time and
contribute to the production of non-collagenous ECM with scaf-
folding function for collagen fibrosis. Our data indicate that TGF-
b plays a central role in the reprogramming as addition of TGF-b
to fibrosis-driving MSCs leads to downregulation of CXCL12
with central role in hematopoiesis support. The increased differ-
entiation of all MSC populations in BM fibrosis can be interpreted
as excessive maldifferentiation, in particular, the osteogenic dif-
ferentiation, which leads to bone formation in the marrow. Mal-
differentiation of MSCs has also been described in other organs
under reactive and regenerative conditions, e.g., the heart (Breit-
bach et al., 2007) and the kidney (Kunter et al., 2007). In the
persistence of a malignant, fibrosis-inducing hematopoietic
clone, MSCs are continuously pushed toward differentiation,
which leads to a vicious cycle of loss of tissue function and scar-
ring with high resemblance to solid organ fibrosis.
Inflammation plays a critical role within this vicious circle and
we here demonstrate that the alarmin heterodimer S100A8/
S100A9 is an important pro-inflammatory player in MPNs with
distinct kinetics: strong expression in hematopoietic cells de-
marcates the myeloproliferative phase and expression in the
stroma demarcates the fibrotic progression. Myeloid cells ex-
press S100A8/S100A9 at baseline (as a marker) but do not
show upregulation in fibrosis/MPNs. Stromal cells, however,
do not express S100A8/S100A9 at steady state but upregulate
the expression in disease. In previous work, we linked increased
S100A8/S100A9 expression in the stroma (where it is not ex-
pressed in healthy individuals) to decreased hematopoiesis
support (Ribezzo et al., 2019), underlining that S100A8/S100A9
might be a good marker for the reprogramming of the stroma
from hematopoiesis support toward fibrotic transformation, in
particular, if followed up in patients over time. Strikingly, Tasqui-
nimod ameliorated the MPN phenotype and fibrosis, suggesting
that it affects both the mutated hematopoietic clone but
also the fibrotic transformation. Our data indicate that pharma-
cological targeting of S100A8/S100A9 has huge translational
value providing first evidence for the design of clinical phase I
studies.
Limitations of study
The aim of our study was to investigate changes in non-hemato-
poietic cells of the BM in the progress of myelofibrosis. It is well
accepted that the isolation process of niche cells is associated
with a bias toward certain cell types (Baccin et al., 2020). Thus,
niche populations can be underrepresented. The number of tools
for inferring ligand-receptor interactions is rapidly increasing.
The overlap between the databases, however, is relatively small.
Identified interactions will need to be validated in the future and
used for prospective curation of the available tools. Finally, liquid
BM frequently cannot be aspirated in advanced myelofibrosis.
Hence, purifying a high number of cells for scRNA-seq is very
challenging. Therefore, the data generated here will be validated
in a larger cohort in the future.
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RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Rebekka
K. Schneider, MD, PhD (reschneider@ukaachen.de).
Materials availability
This study did not generate new unique reagents. For specific details on availability please refer to the Key Resources Table.
Data and code availability
Single cell sequencing experiments are deposited at GEO with accession number GEO: GSE156644. Seurat objects of datasets,
sample markdown code and tables with complete marker genes, differential expression, gene expression enrichment analysis
and ligand receptor analysis are deposited at Zenodo (https://doi.org/10.5281/zenodo.3979087).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animal studies
All mouse studies were approved by the Animal Welfare/Ethics committee of the EDC in accordance with legislation in the
Netherlands (approval No. AVD1010020173387). PtprcaPepcb/BoyCrl (B6.SJL) mice were purchased from Charles River
(Netherlands) and maintained in specific-pathogen-free conditions. Mice were maintained on a 12-hr light/dark cycle and were pro-
vided with water and standard mouse chow ad libitum. Mice were randomly assigned to experimental groups.
Gli1CreERt2 (i.e., Gli1tm3(re/ERT2)Alj/J, JAX Stock #007913), Rosa26tdTomato (i.e., B6-Cg-Gt(ROSA)26Sorttm(CAG-tdTomato)
Hze/J JAX Stock #007909) were purchased from Jackson Laboratories (Bar Harbor, ME, USA). Offspring was genotyped by PCR
according to the protocol from the Jackson laboratory.
Human studies
Forsinglecell studies frombonemarrowbiopsiesonlyexcessmaterialwasused. InaccordancewithMEC-2018-1445all patientmaterial
was de-identified at inclusion. Unprocessed bone marrow biopsies were obtained approximately 1-2h after successful bone marrow
biopsy via the Department of Pathology. More detailed information on patient characteristics can be found in Figures S7A and S7C.
MPN Patient plasma samples were collected and supplied by the University Clinic Hamburg-Eppendorf (UKE), obtained via the
German Study GroupMPNAachen and the Department forMolecular Diagnostics at the ErasmusMedical Center (MC) in Rotterdam.
Control samples were obtained via the Institute for Clinical Chemistry at Erasmus MC. Surplus material was collected from derma-
tological, and cardiological, orthopedic or neurological patients after diagnostics according to the ethical vote MEC-2018-1445 and
processed on the day of acquisition. All subjects had no history or indication of any hematological or non-hematological malignancy.
Samples were de-identified at the time of inclusion. All patients provided informed consent and the data collection was performed in
accordance with the Declaration of Helsinki.
For samples fromBernall patients andhealthydonors gavewritten informedconsent andall analyses of the sampleswereapproved
by the Cantonal Ethics Committee of Bern (2016-01949). Human bone marrow tissues were provided by the Tissue Bank Bern.
Human bonemarrow biopsies from a subcohort of patients whose plasmawas usedwere chosen for histological examination from
archived patient samples of paraffin-embedded tissue from the Biobank of Dr. G. B€usche at the Department of Pathology, Hannover
Medical School, Hannover, Germany. Biopsies were primarily taken during earlier hospitalization. Additional control bone marrow
slides were acquired from the Department of Pathology at Erasmus Medical Center. All reference patients showed normal bone
marrow characteristics and had no evidence for a history of hematological malignancies.
Cell lines and cell culture
ForMSC isolation, bones ofWTmicewere crushed and digestedwith Collagenase II (Invitrogen, #17101015) for 90min at 37C. Bone
chips were washed three times with alpha-MEM/ 10% FCS/ 1% Penicillin/Streptomycin, transferred to a 15cm culture dish and
cultured in full medium (alpha-MEM, 10% FCS, 1% Penicillin/Streptomycin, 1ng/ml murine bFGF (Peprotech, #450-33), 5ng/ml mu-
rine EGF (Peprotech #315-09)). After 72h bone chips were transferred to a new culture dish to dispose of contaminating macro-
phages. After 7–9 days, the bone chips were discarded. Attached MSCs were washed, trypsinated, centrifuged, and replated. Cells
were passaged every 2-4 days at approximately 80% confluence.
METHOD DETAILS
Viral transduction
For retroviral and lentiviral transduction, c-kit+-enriched cells from 8-12-week-old WTmice were isolated by crushing compact bone
and lineage depleted by magnetic separation (Miltenyi Biotec). c-kit+ BM cells were pre-stimulated for 24 h in CellGro media (Cell-
Genix) supplemented by murine stem-cell factor (m-Scf., 50ng/ml, Peprotech) and murine thrombopoietin (m-Tpo, 50ng/ml, Pepro-
tech). Oncoretroviral vectors were pseudotyped with an Ecotropic Envelope Vector and produced using standard protocols.
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Retroviral transductionwas performed on retroNectin (Takara Bio)-coated cell culture dishes loadedwith unconcentrated virus. Cells
were resuspended in medium containing concentrated virus in the presence of 4 mg/ml polybrene at 37C for a minimum of 24 h.
Lentiviral particles were produced by transient transfection with lentiviral plasmid together with pSPAX and VSVG packaging plas-
mids using Fugene (Promega). Lentiviral and retroviral particles were concentrated by ultracentrifugation at 4C.
Induction of myelofibrosis by overexpression of ThPO or JAK2V617F
8-10-week-old female B6.SJL recipients mice were irradiated with 10.5 Gy and received 4-5x105 cells from 8-week-old WT litter-
mates that had been harvested 48 h prior to transplantation and transduced with ThPO (GFP+) lentivirus or control empty vector lenti-
virus (Empty Vector-GFP+). For JAK2V617F studies (JAK2), WT BM cells were transduced with JAK2V617F retrovirus or control pMIG
retrovirus (control: JAK2 empty vector).
Mice from the early ThPO cohort were sacrificed 5 weeks post-transplant andmice in the late ThPO cohort were sacrificed
10 weeks post-transplant. Mice used in the JAK2 experiments were sacrificed at 26 weeks post-BM transplant. Mice in the JAK2
and ThPO late cohort were sacrificed when they had signs of advanced fibrosis as indicated by dropping hemoglobin levels and
apparent weight loss.
Blood was periodically collected from mice via submandibular bleeds into Microtainer tubes coated with K2EDTA (Becton Dick-
inson, NJ, USA) and complete blood counts were performed on a Horiba SciI Vet abc Plus hematology system.
For the quantification of MSC-1/2 and MSC-3/4 in ThPO-setting, 6-10 week old B6.Cg-Tg(Grem1-cre/ERT)3Tcw/J recipient mice
were injected 4x30mgwith tamoxifen in corn oil/ 3%ethanol (Sigma) intraperitoneally. Threeweeks after last tamoxifen injection,mice
were irradiated using a split-scheme of 23 6.02Gy and received 4-5x105 cells from 8-week-old littermates that had been harvested
48 h prior to transplantation and transduced with ThPO (GFP+) lentivirus or control empty vector lentivirus (Empty Vector-GFP+).
Isolation of bone marrow stromal cells for scRNA sequencing
After sacrifice bones (femurs, hip, spine) were crushed and flushed in PBS/2% FCS on ice. The cells were dissociated by filtering
through a 70mm nylon mesh. Cells were lineage depleted using biotinylated antibodies directed against lineages (CD5, CD45R
(B220), CD11b, Anti-Gr-1 (Ly-6G/C), 7-4 and Ter-119) (Miltenyi Biotec) andCD45, CD71 andCD41 (Biolegend). The cells were stained
for 10 min at 4C. After washing, the cells were incubated with anti-biotin beads (Miltenyi biotec) for 15 min at 4C prior to magnetic
depletion using a cell separation magnet (BD). The cells that were not bound to the magnet were used for FACS staining and sorting.
Human biopsies were crushed and flushedwith PBS/10%FCS on ice and filtered through a 70mmnylonmesh. Cleaned bone chips
were digested in 10ml collagenase II (1mg/ml) at 37C for 90 min under gentle agitation. The cell suspension was strained through a
70mmmesh and bone chips were additionally washed twice with PBS/10% FCS before pooling it with the flushed fraction. Both frac-
tions were used for FACS staining and sorting.
FACS-staining and sorting of bone marrow stromal cells for scRNA sequencing
Cells were resuspended in 300ml PBS/2% FCS and stained at 4C for 20 min with the antibodies described below. Washing was per-
formed by adding 1ml PBS/2% FCS and centrifuging for 5min at 3003 g, 4C. After resuspension and addition of Hoechst (1:10000),
lineage/CD45/Ter119 negative cells were sorted into 50ml DMEM/10%FCS (BDAria III) and used for the 10x platform. Unstained cells
were used as negative controls to define gating. All antibodies were acquired from Biolegend.
The following fluorochrome conjugated antibodies were used for murine samples: CD41-APC-Cy7, CD3-APC-Cy7, CD11b-APC-
Cy7, Gr1-APC-Cy7, Ter119-APC-Cy7, B220-APC-Cy7, CD45.1-APC-Cy7, CD45.2-APC-Cy7, Sca1-PerCP, CD31-APC, CD51-PE.
Patient derived cells were stained following the same protocol using the following conjugated antibodies: CD105-APC, CD271-PE,
CD31-APC-Cy7, CD45-FITC, CD235a-FITC, CD71-FITC, CD41-FITC, CD61-FITC
Isolation of Gli1+ stromal cells in homeostasis for scRNaseq
For lineage tracing, 6-7 week old mice were injected intraperitoneally with 4x3 mg tamoxifen in corn oil / 3% ethanol (Sigma). Mice
were sacrificed 2 weeks after the last injection of tamoxifen. At sacrifice, compact bones were crushed and flushed in PBS/2% FCS
and dispersed into a single cell suspension prior to red blood cell lysis to obtain the bone marrow fraction. Bone chips were digested
with Liberase (0.2mg/ml; 5401020001, Roche) in the presence of DNase I (60Units/mL, DN25-100MG) for 30 min at 37C with agita-
tion. The cell suspension was then filtered through a 70mm nylon mesh and combined with the bone marrow fraction before addition
of Hoechst (1:10000). Viable Gli1-tdTom+ cells were sorted (BD Aria II) into DMEM/10% FCS and used for the 10x platform.
Single cell library preparation and sequencing
The libraries were prepared using the Chromium Single Cell 30 Reagent Kits (v2): Single Cell 30 Library & Gel Bead Kit v2 (PN-120237),
Chromium Single Cell A Chip Kit v2 (PN-120236) and i7 Multiplex Kit (PN-120262) (10x Genomics), and following the Single Cell 30
Reagent Kits (v2) User Guide (manual part no. CG00052, Rev D). Finalized libraries were sequenced on a Novaseq6000 platform (Il-
lumina), aiming for a minimum of 50.000 reads/cell using the 10x Genomics recommended number of cycles (28-8-0-91 cycles).
Single cell RNA seq data analysis of ThPO and Jak2 mouse models
Weused cellranger (version 2.1.1) to align reads tomouse genomemm10 and for detection of cells with default parameters. Next, we
used Seurat (v3.1.0) for high level analysis of the scRNA-seq (Satija et al., 2015). We filtered cells with a high amount of mitochondrial
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genes (< 0.1), high amount of ribosomal genes (< 0.25). We also removed cells with more than 30.000 UMIs as they represent po-
tential multiplets. Finally, we filtered cells with less than 30 genes detected. See Table S1 for quality statistics of RNA-seq libraries.
Next, we regressed out cell cycle, the proportion ofmitochondrial, ribosomal andUMI counts and performed a log-normalization of
read counts using Seurat for data. Next, samples from ThPO (and Jak2) experiments were integrated with canonical correlation anal-
ysis (CCA) based on the first 15 CCs (Butler et al., 2018). Unsupervised clustering was performed selecting k = 15 with a shared near-
est neighbors graphwith resolution 0.8. UMAP representations were generated using the following parameters: min_dist = 0.3, max.-
dim = 2, seed.use = 36). We used FindMarkers gene function with adjusted p value < 0.05 to find cluster specific makers.
Differential gene expression analysis was performed with Seurat changing between distinct phenotypes. For this, we consid-
ered only genes with an absolute fold change greater than 0.5 and adjusted p value < 0.01. GO and pathway enrichment analysis
were based on clusterProfiler (Version 3.12.0; (Yu et al., 2012)) and CAMERA from edgeR (Version 3.26.7;(McCarthy, Chen and
Smyth, 2012)). Obtained GO terms were summarized via the REVIGO web application using p values as input metric allowing a
similarity of 0.7 (Supek et al., 2011). We have also defined gene sets describing ‘‘hematopoiesis-support,’’ ‘‘MSC progenitor
phenotype,’’ ‘‘non-collagenous ECM’’ and ‘‘collagenous ECM’’ (Table S2). These were used in a pre-ranked GSEA analysis
(Version 4.0; (Subramanian et al., 2005)). All p values were corrected by Benjamini-Hochberg correction. A full list of identified
marker genes and differentially expressed genes for each dataset including corresponding statistics is supplied in Tables S2
and S3.
Integration of single cell RNA seq data of Gli1 sorted cells
We used the previously described computational pipeline for analysis of Gli1 sorted scRNA-seq cells. We filter cells by fraction of
mitochondrial genes (< 0.1), low amount of ribosomal genes (< 0.08) or cells with less than 200 genes detected. The Gli1 data
were integrated with the ThPO data using a label transfer procedure from Seurat (v3.1.0). This allowed us to associate Gli1 cells
to the 7 clusters detected in ThPO cells.
Single cell RNA seq data analysis of human samples
Weused the previously described computational pipeline for normalization and integration of human samples. Reads were aligned to
the genome GRCh38 and we filtered cells with high fraction of mitochondrial genes (< 0.2), high fraction of ribosomal genes (< 0.4)
and lower number of UMIs (> 45). Also, cells with less than 200 genes detected and cells with more than 12.000 UMIs were removed.
Integration, clustering analysis was performed by Seurat (v3.1.0) as described before.
Reconstructing cell development trajectories
Weusedmonocle (version 2.12.0, (Trapnell et al., 2014)) to reconstruct the cell development trajectories by combining all mouse data
(ThPO, Jak2 and Gli1 cells) with default parameters. We used the 1000 most relevant genes identified by Monocle’s unsupervised
feature selection approach (dpFeature) for the cell development trajectories reconstructing. Next, we used the Branched expression
analysismodeling (BEAM, version 2.12.0, (Qiu et al., 2017)) to find geneswith branch specific expression patterns. Only geneswith an
adjusted p value < 0.05 were further considered.
PROGENy analysis
PROGENy analysis was conducted as described using the Progeny package (R, V1.11.0) for human andmurine datasets. Reference
Progeny papers for each interrogated cluster the generated list of genes differentially expressed between fibrotic and non-fibrotic
conditions was used. The scala products of obtained log2-fold changes and PROGENy weights were calculated for respective
pathway scores. To estimate significance label permutation was performed 10000 times to generate a Null distribution for each
pathway. The pathway scores were scaled to their respective Null distribution to generate a normalized pathway score.
Ligand-receptor analysis
For ligand-receptor analysis we used the CellPhoneDB (Version 2.0.5) tool with somemodifications ((Vento-Tormo et al., 2018); Efre-
mova et. al, 2020). Aiming to increase the amount of ligand-receptor pairs available, the original databasewas extended byOmniPath
interactions which are publicly available (https://github.com/saezlab/cellphonedb_omnipath; T€urei et al., 2016; (Ceccarelli et al.,
2020)). We used log-normalized and scaled scRNA-seq matrices as input. Gene IDs were converted to ENSEMBl IDs using biomaRt
(Version 1.2.0; (Durinck et al., 2009)) and EWCE (Version 0.99.2; (Skene andGrant, 2016)). Each data expression table was split based
on the respective conditions (experiment versus control for murine datasets and MF versus control for the human dataset). Then,
CellPhoneDB was executed for each dataset using the ‘statistical_analysis’. CPDB results were used to build Ligand Receptor net-
works. We only considered ligand receptor pairs which are expressed in at least 10% of cells of the corresponding cluster in mouse
data. Due to the sparsity of the data and the presence of interactions specific to either the fibrotic or the non-fibrotic bone marrow,
unfiltered LR lists were considered for human data. Only statistically significant interactions (p value < 0.05) were considered for
further analyses. For network plots the expression differences for all inferred ligands and all inferred receptors were averaged for
each pair of cell clusters. For individual LR interactions the difference in mean expression between fibrotic and non-fibrotic condition
was calculated as described below. Next, we ranked the individual receptor (or ligands) by their number of interactions and normal-
ized them to the number of all possible cell-cell interactions to identify the most influential receptor (ligand) regarding all conditions.
For an exhaustive list of ligand-receptor pairs with corresponding statistics, refer to Table S5.
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Quantification of S100A8 in human plasma samples
Plasma was isolated from whole blood anticoagulated with EDTA by centrifugation (20003 g, 7 min) and stored at 80C. Samples
were thawed gently on ice and centrifuged for 5 min at 2500 3 g before further processing. Samples were diluted 1:50 - 1:150 and
S100A8 concentration was quantified using the Human S100A8 DuoSet ELISA (R&D Systems, DY4570-05) according to the manu-
facturer’s instructions. For each run samples with values outside of the respective standard curve were adjusted to the highest or
lowest reliably measurable standard respectively.
Histological and immunohistological analysis
Murine organs were fixed in 4% paraformaldehyde for 24 h and transferred to 70% ethanol. Spleens were weighed before fixation.
Femurs were decalcified in 10% EDTA/Tris-HCl (pH 6.6) solution for 72 h, dehydrated, and paraffin embedded. H&E and reticulin
staining were performed on 4 mm sections according to established routine protocols.
Human bone marrow biopsies were fixed for 24 h using the Hannover Solution (12% buffered formaldehyde plus 64%methanol),
decalcified (EDTA), dehydrated and embedded in paraffin. For the patients, whose material was used for scRNaseq, fixed and
stained diagnostic slides were obtained via the Department of Pathology at Erasmus MC.
For immunohistochemical analysis of S100A8 and NCAM1 (CD56), antigen retrieval was performed using citrate-buffer in a con-
ventional lab microwave (Vector, antigen unmasking solution). Sections were treated with 3% H2O2 and blocked with Avidin/Biotin
blocking kit (Vector), and subsequently incubated with primary antibody (rabbit-anti-S100A8: ab92231, Abcam, 1:200; rabbit-anti-
CD56: RBK050, Zytomed Systems, 1:100) for 1 h at room temperature. Biotinylated monoclonal goat anti-rabbit-antibody (Vector)
was used as a secondary antibody for 30 min at room temperature. Slides were incubated with AB complex for 30 min at room tem-
perature, washed, and incubated for a further 10 min with DAB substrate. Slides were counterstained with hematoxylin andmounted
with glass coverslip using DPX mountant (Sigma).
Immunohistochemical stainings for S100bwere performed with an automated, validated, and accredited staining system (Ventana
Benchmark ULTRA, Ventana Medical Systems, Tucson, AZ, USA) using optiview universal DAB detection Kit (#760-700). In brief,
following deparaffinization and heat-induced antigen retrieval the tissue samples were incubated with rabbit-anti-S100-antibody
(DAKO) diluted 1:6000 for 16min at 36C. Incubation was followed by hematoxylin II counter-stain for 12min and then a blue coloring
reagent for 8 min according to the manufacturer’s instructions (Ventana).
Slides were scanned and digitized in an automated fashion using a Hamamatsu Nanozoomer 2.0 HT system. Images were
analyzed and exported using the NDP.view software (Hamamatsu, V2.5.19).
Co-staining of human bone marrow samples for S100b/IL-33
Double immunostaining was performed by automated staining using a Bond RX immunostainer (Leica Biosystems). In brief, all slides
were dewaxed in Bond dewax solution (#AR9222, Leica Biosystems). Heat-induced epitope retrieval was done at pH 9 in Tris buffer
(#AR9640, Leica Biosystems) for 30 min. at 95C. The primary antibodies were incubated sequentially. In a first step, goat anti-IL-33
antibody (#AF3626, R&D Systems) was diluted 1:400, incubated for 30 min, and a rabbit anti-goat antibody (#E0466, Dako) was used
at a 1:400 dilution for 15 min as secondary antibody. All samples were subsequently incubated with horseradish peroxidase (HRP)-
polymer for 15min. and thereafter visualized using 3,3-Diaminobenzidine (DAB) as brown chromogen (#DS9800, bond polymer refine
detection, Leica Biosystems) for 10 min. In a second step, a rabbit anti-S100 antibody (#Z0311, Dako) was diluted 1:6000 and incu-
bated for 30 min. This antibody was detected using a kit solution containing a polymeric alkaline phosphatase (AP)- linker antibody
conjugate system (for 15 min.) and visualized using fast red as red chromogen (#DS9390, red polymer refine detection, Leica Bio-
systems). Finally, the samples were counter-stained with Haematoxylin and mounted with Aquatex (#108562, Merck).
FACS-staining and sorting of MSC-1/2 and MSC-3/4 for functional analysis
Primary murine stromal cells were used at passage 1. The following fluorochrome conjugated antibodies were used: CD45-ef450
(BioLegend, 103125), CD11b-ef450 (ThermoFisher, 48-0112-80), CD140a-PE-Cy7 (BioLegend, 135911), CD140b-APC (Thermo-
Fisher, 17-1402-82), CD106(VCAM-1)-PE (BioLegend, 105713), Lamp-1-FITC (BD PharMingen, 553793), CD63-APC-Cy7(BioLe-
gend), and Hoechst 33342 (BD PharMingen, 561908) for live staining. Cells were sorted from the singlet alive CD45neg CD11bneg
gate. MSC 1+2 was sorted as: CD140a+/CD140b+/VCAM-1+/CD63+/Lamp-1+. MSC 3+4 were sorted as: 1) CD140a+/CD140b+/
VCAM-1+/CD63-/Lamp-1-, and as 2) CD140a-/CD140b-/VCAM-1+. Cells were either seeded directly for CFU-F assay or expanded
in culture.
CFU-F assay
1,000 sort-purified primary cells were seeded per well in a 6-well adherent tissue culture plate usingMesenCult Expansion Kit (STEM-
CELL Technologies), in the presence of MesenPure (STEMCELL Technologies), and 0.5% penicillin-streptomycin. On day 15, cells
were stained with Giemsa (Merck) according to standard protocol and colonies were counted manually.
Growth curve
Sorted cells were cultured in alpha-MEM, 10% FCS, 1% Penicillin/Streptomycin, 1ng/ml murine bFGF (Peprotech, #450-33), 5ng/ml
murine EGF (Peprotech #315-09) in a 6-well plate. Twice a week cells were counted and replated in the same concentration (20.000
cells/well).
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Recombinant cytokine stimulation of primary murine stromal cells
For recombinant cytokine stimulation, primary stromal cells were seeded at 40,000 cells/well in a 6-well plate and stimulated with
recombinant human TGF-b (10ng/ml, Invivogen) for 72 h. Cells were harvested using TriZol (ThermoFisher) and processed for
RNA extraction. 500ng of total RNA was reversely transcribed using the high-capacity cDNA Reverse Transcription kit (Applied Bio-
systems). Quantitative polymerase chain reactions were performed with SYBRGreen PCR master mix (ThermoFisher) on an Applied
Biosystems 7500Real-Time PCRSystem.Glyceraldehyde-3-phosphate dehydrogenase (Gapdh) was used as a housekeeping gene.
Differences in RNA levels were calculated using the 2^-DDCT method. Primer sequences can be found in the Key Resources Table.
MSC to SCP transition
Harvested MSCs were cultured in glutamine-free a-MEM (Sigma) containing 15% FCS.
MSCsat passage 8were seededat 100,000 cells/mL in 1:1 (v/v) DMEM/F12 andNeurobasalmedium (Invitrogen) with basic fibroblast
growth factor (bFGF; 40 ng/mL; Peprotech), epidermal growth factor (20 ng/mL; Peprotech), and B27 (2%, v/v, Invitrogen) in ultra-low-
attachment poly(2-hydroxyethyl methacrylate)-coated culture plates (Corning). Medium was replenished every two days. This non-
adherent fraction was maintained until the neurospheres reached the size of 80-120mm. The neurospheres were seeded onto poly-L-
lysine/laminin-coated culture dishes with a density of 8–10 spheres/cm2. Cultures were maintained in glutamine-free a-MEM (Sigma)
containing 10%FCS and glia inducing factors including forskolin (5 mM;Sigma), platelet-derived growth factor (PDGF)-AA (5 ng/mL; Pe-
protech), bFGF (10 ng/mL; Peprotech), and b-heregulin (200 ng/mL; Millipore) for 10 days. Medium was refreshed every 3 days.
Treatment of mice with Tasquinimod
WT recipient mice (n = 7-10/group) were lethally irradiated (10.5Gy) and transplanted with c-kit+ HSPCs that were retrovirally trans-
duced with either JAK2V617F- or JAK2WT as described above. Tasquinimod treatment (ABR-215050, Biorbyt) was administered via
drinking water at 30mg/kg/day dissolved in 3% sucrose in autoclaved water. Tasquinimod was first dissolved in DMSO, then mixed
with 3% sucrose, 2% PEG300 (Sigma) in water. Vehicle-treated groups received DMSO-, PEG300-treated water with 3% sucrose.
Drinking bottles were renewed twice a week. Treatment was started at 5 weeks post-transplant until 10 weeks post-transplant and
resumed at 13 weeks post-transplant until sacrifice.
Treatment of cells with Tasquinimod
For in vitro studies using Tasquinimod, 20,000 Gli1+ tdTom+ stromal cells were seeded per well in a 6-well plate, in aMEM supple-
mented by 20% FCS, 1ng/ml bFGF (Peprotech, #450-33), 5 ng/ml murine EGF (Peprotech #315-09). At 24 and 48 h after seeding,
cells were treated with recombinant TGF-b (10ng/ml, Invivogen) or PBS control, followed by Tasquinimod treatment (50uM) or
DMSOcontrol. For confocal imaging of in vitro Tasquinimod experiments, Gli1+ tdTom+ stromal cells (20,000 cells/well in 6-well plate)
were cultured on glass coverslips and treated as described above. At 72 h post-seeding, cells were fixed in 4%paraformaldehyde for
10min at room temperature. Cells were stainedwithmouse primary antibody aSMA-FITC (1:100, Sigma, F3777), counterstainedwith
DAPI (40,60-0diamidino-2-phenylindole) and mounted in Prolong Diamond. Images were obtained by confocal microscopy on a Leica
SP8 microscope.
Image processing
All plots were generated with GraphPad Prism Version 8.0 or R Version 3.6.1. To ensure readability line thickness, labels and font size
were adjustedmanually using Adobe Illustrator CC 2018. For joint plotting only identically scaled graphswere used. Unless otherwise
specified, images were representatively chosen and jointly rescaled, before manual alignment if necessary.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis - excluding that for single cell RNaseq data - was conducted using either GraphPad Prism Version 8.0 or R Version
3.6.1. Unless otherwise specified, data are presented as mean ± SEM. Two independent groups with (approximately) normally
distributed samples were compared with an unpaired t test. When normality could not be assumed, Wilcoxon Rank Sum test was
used. For R 2 groups and continuous response variables, ANOVA was employed with post hoc paired t test and Holm-Bonferroni
correction for multiple hypothesis testing. For R 2 groups and discrete/ordinal response variables, Kruskal-Wallis H test with post
hoc pairwise Wilcoxon Rank Sum test was performed.
For trend analysis the Jonckheere-Terpstra-test was employed. p values were calculated for each researcher independently and
corrected for multiple hypothesis testing by the Benjamini–Hochberg procedure.
p values lower or equal to 0.05 were considered statistically significant. Significance is depicted throughout the manuscript as fol-
lows: p % 0.05: *; p % 0.01: **; p % 0.0001: ***.
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